top of page
logo

Retatrutide: What Does the Research Actually Show?

Retatrutide research explained in plain language, including how the triple-agonist works, what clinical trials have found, safety findings, and what researchers still don't know.


Retatrutide has become one of the most closely watched investigational medicines in metabolic research.


Unlike medications that primarily target one or two metabolic hormone receptors, retatrutide is designed to activate three receptors: GIP, GLP-1 and glucagon. Researchers are studying whether this combination can produce substantial changes in body weight, blood sugar and other metabolic measures.


And unlike some emerging compounds that have only been studied in laboratory or animal models, retatrutide has now been evaluated in multiple randomized clinical trials involving thousands of participants.


The results have attracted significant attention.


However, there is an important distinction between promising clinical-trial results and an approved medical treatment.


As of August 2026, retatrutide remains an investigational medicine and has not been approved by the FDA or another regulatory agency. Lilly says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.

So what does the research actually show?


What Is Retatrutide?


Retatrutide, also known by the development code LY3437943, is an investigational peptide-based medicine being developed by Eli Lilly.


It is described as a triple hormone receptor agonist because it activates three receptors:

  • GIP — glucose-dependent insulinotropic polypeptide

  • GLP-1 — glucagon-like peptide-1

  • Glucagon


The goal is to combine biological effects associated with all three signaling pathways in a single molecule.


Lilly's current development pipeline describes retatrutide as a GIP/GLP-1/glucagon receptor agonist being studied for obesity and related conditions, including knee osteoarthritis pain, obstructive sleep apnea and metabolic dysfunction-associated steatotic liver disease.


Retatrutide is therefore different from a conventional GLP-1 receptor agonist and from dual GIP/GLP-1 receptor agonists.


Why Are Researchers Studying Retatrutide?


The scientific interest in retatrutide comes largely from the possibility that simultaneously activating three metabolic pathways could produce effects beyond those achieved by targeting fewer receptors.


GLP-1 signaling is associated with appetite regulation, glucose control and gastrointestinal effects.


GIP signaling is involved in glucose and energy metabolism.


Glucagon has effects that include increasing energy expenditure and influencing glucose and lipid metabolism.


The idea behind retatrutide is not simply to add three unrelated effects together. Researchers are investigating whether coordinated activation of these pathways can produce a different metabolic response.


This is one reason retatrutide has become an important area of obesity and metabolic research.


What Did Earlier Retatrutide Research Show?


Before the current Phase 3 program, retatrutide was evaluated in a randomized Phase 2 trial involving adults with obesity or overweight.


The trial was published in the New England Journal of Medicine in 2023 and enrolled 338 adults.


At 48 weeks, the study reported substantial average reductions in body weight in the retatrutide groups compared with placebo. The reported least-squares mean changes ranged from approximately 8.7% in the 1-mg group to 24.2% in the 12-mg group, compared with 2.1% with placebo.


The study also reported that gastrointestinal adverse events were the most common adverse events and were generally mild to moderate. Dose-dependent increases in heart rate were also observed.


These Phase 2 findings helped establish the rationale for larger Phase 3 studies.

But Phase 2 results are not the final test of a medicine.


Larger Phase 3 trials are designed to provide more extensive information about effectiveness and safety.


What Have Phase 3 Trials Found?


By 2026, Lilly had reported positive topline results from several Phase 3 trials.

These results are important because they move the evidence base considerably beyond the earlier laboratory and Phase 2 research.


TRIUMPH-1


In May 2026, Lilly announced results from TRIUMPH-1, a Phase 3 trial involving adults with obesity or overweight and at least one weight-related condition who did not have diabetes.


At 80 weeks, Lilly reported average weight reductions of:

  • 19.0% with 4 mg

  • 25.9% with 9 mg

  • 28.3% with 12 mg

The placebo group had substantially less weight reduction.


Lilly also reported that 45.3% of participants receiving 12 mg achieved at least 30% weight loss.


These are substantial results.


However, it is important to identify them correctly: these are company-reported topline Phase 3 results, rather than evidence that retatrutide has already received regulatory approval.


TRIUMPH-2: Retatrutide and Type 2 Diabetes


TRIUMPH-2 studied adults with obesity or overweight and type 2 diabetes.

Lilly reported that at 80 weeks participants receiving retatrutide lost an average of:

  • 12.7% with 4 mg

  • 19.1% with 9 mg

  • 20.8% with 12 mg


The company also reported improvements in A1C, with reductions of up to an average of 1.6 percentage points.


This trial is particularly relevant because weight management can be more challenging in people with type 2 diabetes than in people without diabetes.


The results provide additional evidence that retatrutide has substantial metabolic effects in a population with diabetes.


TRIUMPH-3: Obesity and Cardiovascular Disease


TRIUMPH-3 examined adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.


Lilly reported average weight reductions at 80 weeks of up to:

22.6%


or approximately 55.8 pounds, depending on the analysis and dose.


This population is particularly important because obesity and cardiovascular disease frequently occur together.


However, weight reduction should not automatically be interpreted as proof that retatrutide prevents cardiovascular events.


That question requires dedicated clinical-outcome evidence.


TRANSCEND-T2D-1


Retatrutide has also been studied specifically in adults with type 2 diabetes.

In March 2026, Lilly announced results from TRANSCEND-T2D-1.


At 40 weeks, Lilly reported average A1C reductions ranging from approximately 1.7 to 2.0 percentage points, depending on dose.


Participants receiving 12 mg experienced an average weight reduction of 16.8%.

Lilly subsequently presented additional information from the trial showing improvements in several cardiometabolic measurements, including systolic blood pressure, non-HDL cholesterol and triglycerides.


Again, these findings are clinically interesting, but they should not be confused with evidence that retatrutide is already an approved treatment.


How Does Retatrutide Compare With GLP-1 Approaches?


One reason retatrutide has generated so much interest is its mechanism.

A traditional GLP-1 receptor agonist primarily targets the GLP-1 receptor.

Tirzepatide targets both GIP and GLP-1 receptors.


Retatrutide targets:

GIP + GLP-1 + glucagon

The scientific question is whether adding glucagon receptor activity to GIP and GLP-1 signaling can produce additional metabolic effects.


The Phase 2 study provided evidence that retatrutide can produce substantial weight loss, and the subsequent Phase 3 program has produced even larger reported effects in several populations.


However, direct comparisons between different medicines need to be interpreted carefully.


A result from one clinical trial cannot automatically be compared with a result from another trial because the populations, study designs, endpoints and durations may differ.


The strongest comparisons come from appropriately designed head-to-head clinical trials.


What About Retatrutide and Metabolism?


Researchers aren't interested in retatrutide solely because of changes on the scale.

Clinical studies have also evaluated measures such as:

  • Blood glucose

  • A1C

  • Waist circumference

  • Blood pressure

  • Lipids

  • Inflammatory biomarkers

  • Other metabolic measurements

The 2026 Phase 3 results reported by Lilly have shown improvements across several of these measures.


These findings help explain why researchers are investigating retatrutide across a broader range of cardiometabolic conditions.


But improvements in laboratory or physiological measurements do not automatically mean that every potential long-term health outcome has been established.


What Are the Safety Findings?


Safety is one of the most important parts of any clinical development program.

The Phase 2 trial reported that gastrointestinal adverse events were the most common adverse events. They were generally described as mild to moderate and were related to dose.


The Phase 2 trial also observed dose-dependent increases in heart rate, with the increase peaking around 24 weeks and declining afterward.


The larger Phase 3 program is designed to provide substantially more information about the safety profile.


However, the fact that clinical trials have produced safety data does not mean every potential long-term risk has been completely characterized.


Long-term safety surveillance is an important part of pharmaceutical development.


What Researchers Still Don't Know


Despite the growing evidence base, several questions remain.


Long-term outcomes

Retatrutide has not yet accumulated the decades of post-approval safety experience associated with established medications.


Cardiovascular outcomes

Changes in cardiovascular risk factors are not the same thing as demonstrating reductions in heart attacks, strokes or cardiovascular mortality.

Dedicated outcome studies are needed to answer those questions.


Long-term weight maintenance

Researchers need to understand what happens after treatment is stopped and how durable weight reduction is over longer periods.


Broader populations

Clinical trials have specific inclusion and exclusion criteria. Results from trial populations do not necessarily apply equally to every person.


Regulatory status

Positive Phase 3 findings do not equal FDA approval.

As of August 2026, retatrutide remains investigational. Lilly has stated that it plans to submit a BLA to the FDA in Q1 2027.


Is Retatrutide FDA Approved?

No.


As of August 2026, retatrutide has not been approved by the FDA or any other regulatory agency, according to Lilly's current public information.


The FDA explains that drugs being tested but not yet approved are considered investigational or experimental drugs.


This distinction is particularly important because retatrutide is now receiving considerable attention online.


Lilly specifically warns consumers against products sold as retatrutide outside Lilly-sponsored clinical trials and states that such products may contain incorrect amounts, contaminants, impurities or even the wrong active ingredient.


Common Retatrutide Claims vs. What the Evidence Shows


“Retatrutide is just another GLP-1.”

What the research shows:Retatrutide is different from a GLP-1-only approach because it activates GIP, GLP-1 and glucagon receptors.


“Retatrutide is proven to cause 30% weight loss in everyone.”

What the research shows:Some Phase 3 participants achieved very large weight reductions, but clinical-trial averages and individual outcomes are not the same thing. Results vary between participants and study populations.


“Retatrutide is FDA approved.”

What the research shows:No. It remains investigational as of August 2026.


“Retatrutide has only been tested in animals.”

What the research shows:Incorrect. Retatrutide has now been studied in multiple human Phase 2 and Phase 3 clinical trials.


“The clinical trial results prove long-term safety.”

What the research shows:Clinical trials provide important safety information, but ongoing research and longer-term surveillance are necessary to characterize the full safety profile of a new medicine.


Frequently Asked Questions


What is retatrutide?

Retatrutide is an investigational peptide-based medicine that activates GIP, GLP-1 and glucagon receptors. It is being developed by Eli Lilly.


Is retatrutide a GLP-1?

Not exactly. Retatrutide activates the GLP-1 receptor, but it also activates the GIP and glucagon receptors, making it a triple receptor agonist.


Has retatrutide been studied in humans?

Yes. Retatrutide has been evaluated in randomized clinical trials, including Phase 2 and multiple Phase 3 studies.


Is retatrutide FDA approved?

No. As of August 2026, it remains investigational and has not been approved by any regulatory agency.


What have clinical trials found?

Clinical trials have reported substantial average reductions in body weight as well as improvements in measures such as A1C and other cardiometabolic markers. Results vary by study population and dose.


Is retatrutide available as an approved medication?

No. It remains in clinical development. Lilly has said it plans to submit a BLA to the FDA in the first quarter of 2027.


The Bottom Line

Retatrutide is one of the most advanced investigational compounds currently being studied in metabolic medicine.


Unlike many emerging research compounds, its evidence base now includes multiple randomized human clinical trials.


The results reported in 2026 have shown substantial average weight reductions and improvements in several metabolic measurements across different populations.


The underlying concept is also scientifically distinctive: retatrutide simultaneously targets GIP, GLP-1 and glucagon receptors.


But the research story isn't finished.


Retatrutide remains investigational. It has not been approved by the FDA, and questions surrounding long-term safety, durability of effects and broader clinical outcomes remain part of the ongoing development program.


The most accurate way to describe retatrutide today is therefore:

A promising investigational triple-receptor agonist with substantial human clinical evidence, but not yet an approved medicine.


Sources & Further Reading


Educational Disclaimer

This article is provided for educational and research-information purposes only. It is not medical advice, diagnosis or treatment. Retatrutide is an investigational medicine and has not been approved by the FDA. Clinical-trial results should not be interpreted as an instruction or recommendation to use an investigational drug.


Explore the Research

Interested in exploring the compounds discussed in this article?

Visit Latitude 40 Aminos to explore our research-compound catalog and available product information.

 
 
 

Comments

bottom of page